Vivos Therapeutics (NASDAQ:VVOS – Get Free Report) and Tandem Diabetes Care (NASDAQ:TNDM – Get Free Report) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, institutional ownership, risk, dividends, valuation and earnings.
Insider and Institutional Ownership
26.4% of Vivos Therapeutics shares are held by institutional investors. 1.4% of Vivos Therapeutics shares are held by company insiders. Comparatively, 2.1% of Tandem Diabetes Care shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Earnings & Valuation
This table compares Vivos Therapeutics and Tandem Diabetes Care”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vivos Therapeutics | $17.44 million | 0.10 | -$21.17 million | ($1.90) | -0.05 |
| Tandem Diabetes Care | $1.01 billion | 1.29 | -$204.71 million | ($0.72) | -25.99 |
Vivos Therapeutics has higher earnings, but lower revenue than Tandem Diabetes Care. Tandem Diabetes Care is trading at a lower price-to-earnings ratio than Vivos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent ratings and recommmendations for Vivos Therapeutics and Tandem Diabetes Care, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vivos Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
| Tandem Diabetes Care | 1 | 12 | 9 | 1 | 2.43 |
Vivos Therapeutics currently has a consensus price target of $2.80, indicating a potential upside of 3,144.50%. Tandem Diabetes Care has a consensus price target of $27.18, indicating a potential upside of 45.29%. Given Vivos Therapeutics’ higher probable upside, analysts clearly believe Vivos Therapeutics is more favorable than Tandem Diabetes Care.
Risk and Volatility
Vivos Therapeutics has a beta of 6.37, suggesting that its share price is 537% more volatile than the S&P 500. Comparatively, Tandem Diabetes Care has a beta of 1.59, suggesting that its share price is 59% more volatile than the S&P 500.
Profitability
This table compares Vivos Therapeutics and Tandem Diabetes Care’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vivos Therapeutics | -122.00% | -2,325.64% | -102.01% |
| Tandem Diabetes Care | -4.58% | -35.61% | -4.53% |
Summary
Tandem Diabetes Care beats Vivos Therapeutics on 10 of the 14 factors compared between the two stocks.
About Vivos Therapeutics
Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing oral appliances and related treatments for sleep-disordered breathing, including obstructive sleep apnea (OSA) and snoring. Its approach is designed to help improve upper-airway function through non-surgical, dentist-supervised therapies. The company’s primary products are its Vivos Complete Airway Repositioning and Expansion (CARE) oral appliances, which are customized for individual patients and intended for use during sleep.
About Tandem Diabetes Care
Tandem Diabetes Care develops and commercializes technology for people who use insulin to manage diabetes. Its products include insulin pumps, infusion sets and related supplies, along with software for viewing and sharing diabetes-management data. The company’s offerings include the t:slim X2 insulin pump and the Tandem Mobi pump, as well as Control-IQ technology, which can automatically adjust insulin delivery based on continuous glucose monitor readings when used with compatible devices. Tandem also provides mobile apps and cloud-based tools to support users and healthcare providers.
Receive News & Ratings for Vivos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vivos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
